Meropenem Kalceks (Meropenem)

Meropenem is a carbapenem antibiotic indicated for severe infections affecting specific organ systems.

• Complicated intra‑abdominal infections: provides broad‑spectrum coverage against Gram‑negative, Gram‑positive and anaerobic bacteria, facilitating infection resolution.
• Complicated urinary tract infections: eradicates resistant uropathogens, including ESBL‑producing organisms.
• Nosocomial pneumonia: effective against hospital‑acquired respiratory pathogens, including Pseudomonas aeruginosa.
• Septicemia: delivers rapid bactericidal activity in bloodstream infections caused by susceptible organisms.

• Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis. The drug shows high affinity for a broad range of PBPs, accounting for its activity against many Gram‑negative, Gram‑positive and anaerobic organisms, including those resistant to other β‑lactams.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Diarrhea: loose stools that may be watery and occur intermittently.
• Nausea: sensation of queasiness that can lead to occasional vomiting.
• Headache: mild to moderate cranial pain often resolving without treatment.
• Elevated liver enzymes: transient rise in ALT/AST without clinical hepatitis.
• Injection site pain: discomfort or erythema at the intravenous access point.

Serious or Rare Side Effects

• Seizures: convulsive episodes, more likely in patients with renal dysfunction or pre‑existing CNS disease.
• Severe allergic reactions: anaphylaxis, urticaria, or angioedema requiring immediate medical intervention.
• Clostridioides difficile colitis: severe diarrhea with pseudomembranous colitis following antibiotic exposure.

When using Meropenem, several precautions should be observed to ensure safe and effective therapy.

• Renal function assessment: adjust dose in patients with impaired kidney function.
• Hypersensitivity screening: avoid use in individuals with known carbapenem or β‑lactam allergy.
• Monitor for seizures: observe neurological status, especially in patients with CNS disorders.
• Liver function monitoring: check transaminases during prolonged therapy.
• Concomitant nephrotoxic drugs: use caution when combined with other agents that affect renal function.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Valproic acid: concomitant use may reduce valproate levels, risking seizure breakthrough.
• Probenecid: may decrease renal clearance of Meropenem, increasing toxicity risk.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: additive nephrotoxicity; monitor renal function.
• Loop diuretics: may enhance renal toxicity; assess kidney parameters.
• Anticoagulants (e.g., warfarin): possible alteration of INR; check coagulation status.